Single-group proof-of-concept IV ketamine study (n=5) testing a single 0.5 mg/kg (40 min) infusion in patients with comorbid major depressive episode and alcohol dependence.
Proof-of-concept study assessing the effect of a single intravenous ketamine infusion (0.5 mg/kg over 40 minutes) on depressive symptoms in patients with current major depressive episode and alcohol dependence.
Primary outcome planned as change in depression rating at 72 hours; alcohol consumption and safety/AE monitoring are secondary outcomes. Registry fragments list a single-group intervention with actual enrolment of 5.
Intravenous ketamine 0.5 mg/kg single infusion.
Administered as a 40-minute infusion (Ketalar 0.5 mg/kg).